- Home
- ABEO vs TTRX Comparison
ABEO vs TTRX Comparison
Compare ABEO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$5.05
N/A
Current Price
$3.49
Company Overview
Basic Information| Metric | ABEO | TTRX |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 257.8M |
| IPO Year | 1980 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABEO | TTRX |
|---|---|---|
| Price | $5.05 | $3.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.20 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 105.2K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.71 | N/A |
| P/E Ratio | $3.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $2.57 |
| 52 Week High | $7.54 | $26.50 |
Technical Indicators
Market Signals| Indicator | ABEO | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | N/A |
| Support Level | $4.37 | N/A |
| Resistance Level | $5.17 | N/A |
| Average True Range (ATR) | 0.32 | 0.00 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 65.80 | 0.00 |
Price Performance
Historical Comparison ABEO
TTRX
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.